Publication date: May 11, 2026
Tuberculosis (TB) remains a global challenge, with 10. 8 million cases and 1. 25 million deaths annually. This study aimed to identify baseline characteristics of TB participants associated with treatment failure and death. This retrospective cohort study enrolled adult participants with TB treated between 2015 and 2022 at a Brazilian referral center. Comprehensive baseline data (socioeconomics, demographics, clinicals, and laboratory tests) and monthly follow-up visits data were extracted from electronic medical records. Outcomes followed WHO 2021 criteria. Backward stepwise multivariable regression analysis was performed to identify predictors independently associated with failure and death. Among 485 participants (61. 2% male, median age 38. 0 years), 7. 2% (N = 35) had unfavorable outcomes, comprising 1. 8% death (N = 9) and 5. 4% treatment failure (N = 26), the latter primarily driven by regimen changes due to adverse drug reactions (22/26 cases) rather than microbiological failure. Univariate analysis identified a higher proportion of unfavorable outcomes among people living with HIV (57. 1% vs. 32. 9%; p = 0. 007), as well as in baseline hospitalization (48. 6% vs. 14. 0%; p
Open Access PDF
| Concepts | Keywords |
|---|---|
| 25million | Diabetes mellitus |
| Brazilian | Hospitalization |
| Laboratory | Treatment outcomes |
| Monthly | Tuberculosis |
| Tuberculosis |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | diabetes mellitus |
| disease | MESH | tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | MESH | death |
| disease | MESH | adverse drug reactions |
| disease | MESH | Infectious Diseases |
| disease | MESH | Dis |
| pathway | REACTOME | Reproduction |
| disease | MESH | included |
| drug | DRUGBANK | Ribostamycin |
| drug | DRUGBANK | Coenzyme M |